Traditional anti-cancer treatments used for metastatic melanoma (skin cancer) can result in cell toxicity, poor efficacy, and low patient survival. UCI researchers have uncovered a class of potent compounds that inhibit cancer cell growth and induce cancer cell death by targeting RhoJ signaling pathways.
Melanoma develops from cancer cells in the skin. In nearly all pre-metastatic cases surgical removal of the cancer cells is curative; however, after metastasis traditional cancer treatments can result in cell toxicity, poor efficacy, and low patient survival. Previous studies have implicated the RhoJ signaling pathway in modulating melanoma cell migration, accelerates tumor growth, and inhibits cell death activity. Hence, targeting the RhoJ pathway represents a promising approach to developing anti-cancer drugs.
UCI researchers have discovered a class of small molecules to block RhoJ signaling for treating stage III melanomas or stage IV melanomas resistant to other treatments. They identified potent inhibitors of human RhoJ and other related proteins downstream in the pathway that activate cell death in melanoma cells, while blocking cancer cell proliferation. These therapeutics may be employed as a single or combinatory treatment with other anticancer drugs (e.g., cisplatin). The molecules are permeable to cell membranes in complex biological environments and their scaffold have inherent drug-likeness, which would enable great chemical diversity in anti-cancer drug development. The new compounds provide a promising approach for treating melanoma and other cancers by essentially releasing the downstream block on cell death in cancer cells.
• Treatment of melanoma and disorders associated with increased levels of RhoJ (e.g. hyperplasia, metaplasia or dysplasia, cancer metastasis, hyperproliferative disorders
• Treatment of retinal disorders and cardiomyopathies
• Can be used ether as a stand-alone therapeutic or combinatory chemotherapeutic (e.g. with cisplatin or radiation therapy)
Inhibitory compounds have been identified and validated efficacy in vitro, testing potency with and without second anticancer drug, cisplatin, in melanoma cells.
Ongoing PK studies, bioavailability, and binding affinity of these compounds for in vivo tests